Kadmon : Corporate Presentation

Corporate Presentation

January 20, 2020

Disclaimer

This presentation contains "forward‐looking" statements that are based on the beliefs and assumptions and on information currently available to management of Kadmon Holdings, Inc. (the "Company"). All statements other than statements of historical fact contained in this presentation are forward-looking statements. Forward‐looking statements include information concerning the initiation, timing, progress and results of clinical trials of the Company's product candidates, the timing or likelihood of regulatory filings and approvals for any of its product candidates, and estimates regarding the Company's expenses, future revenues and future capital requirements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other comparable terminology. There are important factors that could cause the Company's actual results to differ materially from those expressed or implied by the forward-looking statements, including those factors discussed under the caption entitled "Risk Factors" in the Company's filings with the U.S. Securities and Exchange Commission ("SEC"), including the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, filed pursuant to Section 13 of the Securities Exchange Act of 1934, as amended, with the SEC.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements represent the Company's beliefs and assumptions only as of the date of this presentation. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward‐looking statements for any reason after the date of this presentation to conform any of the forward-looking statements to actual results or to changes in its expectations.

| 2

About Kadmon

Research		Clinical Pipeline		Commercial Operation

• Late-stagebiopharma company headquartered in New York, NY (NYSE: KDMN)
• Therapeutic focus areas:
• • Immune and fibrotic diseases
  • Immuno-oncology(I-O)
• Lead candidate: Belumosudil, a small molecule ROCK2 inhibitor for the treatment of chronic graft-
  versus-host disease (cGVHD); NDA accepted; PDUFA date: May 30, 2021

| 3

Kadmon Clinical Pipeline

CANDIDATE	INDICATION	STATUS
		• Primary endpoint met in pivotal clinical trial
Belumosudil	Chronic Graft-Versus-Host	• NDA accepted: PDUFA date: May 30, 2021
Disease (cGVHD)	• NDA being reviewed under FDA's Real-Time Oncology Review
(KD025)
	(RTOR) and Project Orbis pilot programs
(Selective ROCK2
inhibitor)		• Placebo-controlled Phase 2 clinical trial ongoing
	Systemic Sclerosis
	• Small open-label Phase 2 clinical trial planned Q1 2021
KD033	Immuno-oncology
(anti-PD-L1/IL-15	• Phase 1 clinical trial ongoing
fusion protein)

| 4